Abstract
Chemoresistance is one of the major reasons for the failure of anticancer chemotherapy in treating advanced stage cancer. The mechanism of chemoresistance to fluoropyrimidines and antifolates has been extensively investigated in the past 40 years. It has been well established that thymidylate synthase (TYMS, TS) and dihydrofolate reductase (DHFR) are two major targets for fluoropyrimidines and antifolates, respectively. The regulatory mechanism of TS and DHFR expression is rather complex involving transcriptional, post-transcriptional and translational regulations. Our recent understanding of the chemoresistance mechanism has been extended beyond the simple one target/drug view. In this review, we will focus on the recent advancement of non-coding microRNAs (miRNAs) in contributing to the regulations of TS and DHFR expression, and to the chemoresistance mechanism of fluoropyrimidines and antifolates.
Keywords: Translational control, microRNA, thymidylate synthase, dihydrofolate reductase, 5-fluorouracil, methotrexate, chemoresistance, lymphocytic leukemia, apoptosis, dihydropyrimidine dehydrogenase
Current Enzyme Inhibition
Title:Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance
Volume: 8 Issue: 2
Author(s): Jingfang Ju
Affiliation:
Keywords: Translational control, microRNA, thymidylate synthase, dihydrofolate reductase, 5-fluorouracil, methotrexate, chemoresistance, lymphocytic leukemia, apoptosis, dihydropyrimidine dehydrogenase
Abstract: Chemoresistance is one of the major reasons for the failure of anticancer chemotherapy in treating advanced stage cancer. The mechanism of chemoresistance to fluoropyrimidines and antifolates has been extensively investigated in the past 40 years. It has been well established that thymidylate synthase (TYMS, TS) and dihydrofolate reductase (DHFR) are two major targets for fluoropyrimidines and antifolates, respectively. The regulatory mechanism of TS and DHFR expression is rather complex involving transcriptional, post-transcriptional and translational regulations. Our recent understanding of the chemoresistance mechanism has been extended beyond the simple one target/drug view. In this review, we will focus on the recent advancement of non-coding microRNAs (miRNAs) in contributing to the regulations of TS and DHFR expression, and to the chemoresistance mechanism of fluoropyrimidines and antifolates.
Export Options
About this article
Cite this article as:
Ju Jingfang, Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance, Current Enzyme Inhibition 2012; 8 (2) . https://dx.doi.org/10.2174/157340812800793228
DOI https://dx.doi.org/10.2174/157340812800793228 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Placental Transport of Folate and Thiamine: A Mini-Review
Current Women`s Health Reviews Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Targeting Plasminogen Activator Inhibitor-1: Role in Cell Signaling and the Biology of Domain-Specific Knock-in Mice
Current Drug Targets Factors Regulating Human Extravillous Trophoblast Invasion: Chemokine-peptidase and CD9-integrin Systems
Current Pharmaceutical Biotechnology Melatonin in Pregnancy: Effects on Brain Development and CNS Programming Disorders
Current Pharmaceutical Design Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Protein & Peptide Letters Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters